Summary
This PoC project aims to pave the road to commercialize a comprehensive data analytics platform enabling data-driven biomedical innovation and precision medicine. The platform is specifically designed to efficiently fuse and mine heterogeneous omic data, including genomes,
epigenomes, proteomes, metabolomes, patient clinical profiles, drugs and their chemical similarities, disease and other
ontologies, and other relevant omic data. The goal of this development is to provide the most advanced software platform for
fusion and analytics of numerous heterogeneous multi-scale omic data that takes advantage of novel non-negative matrix trifactorization
(NMTF)-based and network mining algorithms, providing dramatic improvements in the number and type of
fused data, quantity of data, computational efficiency and biomedical accuracy compared to the most advanced omic data
analytics platforms currently existing.
The main goal of the PoC is to close the gap between the research results of ERC Consolidator Grant, ICON-BIO, and the production of a
commercial data analytics platform for the bio-pharmaceutical sector. In particular, the solution will target biopharma
companies to embed the platform into their existing Data Science resources and enable effective and
efficient application of the platform’s explainable AI methods (resulting from ICON-BIO) to optimize and guide their discovery
processes. The result of this effort will be the achievement of a market-ready Data Analytics Platform.
epigenomes, proteomes, metabolomes, patient clinical profiles, drugs and their chemical similarities, disease and other
ontologies, and other relevant omic data. The goal of this development is to provide the most advanced software platform for
fusion and analytics of numerous heterogeneous multi-scale omic data that takes advantage of novel non-negative matrix trifactorization
(NMTF)-based and network mining algorithms, providing dramatic improvements in the number and type of
fused data, quantity of data, computational efficiency and biomedical accuracy compared to the most advanced omic data
analytics platforms currently existing.
The main goal of the PoC is to close the gap between the research results of ERC Consolidator Grant, ICON-BIO, and the production of a
commercial data analytics platform for the bio-pharmaceutical sector. In particular, the solution will target biopharma
companies to embed the platform into their existing Data Science resources and enable effective and
efficient application of the platform’s explainable AI methods (resulting from ICON-BIO) to optimize and guide their discovery
processes. The result of this effort will be the achievement of a market-ready Data Analytics Platform.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/957488 |
| Start date: | 01-09-2020 |
| End date: | 31-08-2023 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
This PoC project aims to pave the road to commercialize a comprehensive data analytics platform enabling data-driven biomedical innovation and precision medicine. The platform is specifically designed to efficiently fuse and mine heterogeneous omic data, including genomes,epigenomes, proteomes, metabolomes, patient clinical profiles, drugs and their chemical similarities, disease and other
ontologies, and other relevant omic data. The goal of this development is to provide the most advanced software platform for
fusion and analytics of numerous heterogeneous multi-scale omic data that takes advantage of novel non-negative matrix trifactorization
(NMTF)-based and network mining algorithms, providing dramatic improvements in the number and type of
fused data, quantity of data, computational efficiency and biomedical accuracy compared to the most advanced omic data
analytics platforms currently existing.
The main goal of the PoC is to close the gap between the research results of ERC Consolidator Grant, ICON-BIO, and the production of a
commercial data analytics platform for the bio-pharmaceutical sector. In particular, the solution will target biopharma
companies to embed the platform into their existing Data Science resources and enable effective and
efficient application of the platform’s explainable AI methods (resulting from ICON-BIO) to optimize and guide their discovery
processes. The result of this effort will be the achievement of a market-ready Data Analytics Platform.
Status
SIGNEDCall topic
ERC-2020-POCUpdate Date
27-04-2024
Images
No images available.
Geographical location(s)
